• KOL
    • Type 1 Diabetes
    • Roy W Beck
    • Roy W Beck: Influence Statistics

      Roy W Beck

      Roy W Beck

      Show email address

      Jaeb Center for Health Research, Tampa, Florida 33647, USA | Jaeb Center for Health Research Foundation, Inc., Tampa, Florida, USA. | Jaeb Center for Health Research, Tampa, ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Roy W Beck:Expert Impact

      Concepts for whichRoy W Beckhas direct influence:Type 1 diabetes,Optic neuritis,Type 1,Visual acuity,1 diabetes,Continuous glucose monitoring,Glucose monitoring,Diabetic macular edema.

      Roy W Beck:KOL impact

      Concepts related to the work of other authors for whichfor which Roy W Beck has influence:Type 1 diabetes,Multiple sclerosis,Diabetic retinopathy,Visual acuity,Optic neuritis,Macular edema,Glycemic control.

      KOL Resume for Roy W Beck

      Year
      2022

      Jaeb Center for Health Research, Tampa, Florida 33647, USA

      2021

      Jaeb Center for Health Research Foundation, Inc.

      JAEB Center for Health Research, Tampa, Florida, USA.

      Vienna, Austria, Nottingham, United Kingdom, Cambridge, United Kingdom, Leeds, United Kingdom, Aurora, CO, Palo Alto, CA, Southampton, United Kingdom, Indianapolis, IN, Jacksonville, FL, Oxford, United Kingdom, Liverpool, United Kingdom, New Haven, CT, Stanford, CA, Los Angeles, CA, Tampa, FL

      2020

      Jaeb Center for Health Research, Tampa, FL, USA

      2019

      Jaeb Center for Health Research, Tampa, FL, USA. Electronic address:

      Aurora, CO, Denver, CO, Tampa, FL

      2018

      Jaeb Center for Health Research, Tampa, Florida (R.W.B., T.D.R.).

      Deputy Editor, JAMA Ophthalmology

      Santa Barbara, CA, Tampa, FL, Stanford, CA, Aurora, CO, New Haven, CT, San Diego, CA

      2017

      From International Diabetes Center Park Nicollet, Minneapolis, Minnesota; Jaeb Center for Health Research, Tampa, Florida; University Hospitals of Cleveland, Cleveland, Ohio; Henry Ford Health System, Detroit, Michigan; Children's Hospital of Philadelphia and Perelman School of Medicine and Rodebaugh Diabetes Center, University of Pennsylvania, Philadelphia, Pennsylvania; Northwestern University, Chicago, Illinois; SUNY Upstate Medical University, Syracuse, New York; Children's Hospital of Los Angeles, Los Angeles, California; Indiana University School of Medicine, Indianapolis, Indiana; SUNY Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York; and Northwest Lipid Metabolism and Diabetes Research Laboratories, Seattle, Washington.

      Jaeb Center for Health Research, Tampa, Florida 33647.

      2016

      Jaeb Center for Health Research Tampa FL USA

      Deputy editor, JAMA Ophthalmology

      2015

      Jaeb Center for Health Research, Tampa, Florida;

      2014

      Jaeb Centre for Health Research, 15310 Amberly Drive, Suite 350, 33647, Tampa, FL, USA

      2013

      Jaeb Center for Health Research (D.X., S.N.D., K.M.M., R.W.B.), Tampa, Florida 33647

      1, Children’s Hospital Los Angeles, Los Angeles, California

      2012

      Jaeb Center for Health Research, Tampa, Florida (Mr Glassman, Ms Stockdale, and Dr Beck)

      2011

      Jaeb Center for Health Research, Tampa, FL 33647, USA

      2010

      Jaeb Center for Health Research, Tampa, Florida (Mr Kraker and Dr Beck)

      2009

      Tampa, Florida

      2008

      From the Jaeb Center for Health Research, Tampa, Florida;

      Jaeb Center for Health Research, 15310 Amberly Dr, Ste 350, Tampa, FL 33647, USA.

      2007

      From the Neuro-Ophthalmology, INN at Roosevelt Hospital and Albert Einstein School of Medicine, New York, NY (M.J.K.); Jaeb Center for Health Research, Tampa, FL (R.L.G., R.W.B., D.X.); and Wilmer Institute of Ophthalmology, Johns Hopkins School of Medicine, Baltimore, MD (N.M.).

      2005

      The Jaeb Center for Health Research, Tampa, Florida.

      2004

      Jaeb Center for Health Research 
 Tampa, FL 33647

      Tampa, Florida, USA

      2003

      Jaeb Center for Health Research, Tampa, Florida, USA (D.L.C., R.W.B., P.S.M.)

      2002

      Jaeb Center for Health Research, 3010 E. 138th Avenue, Suite 9, Tampa, FL 33613, U.S.A.

      2001

      Jaeb Center for Health Research (P.S.M., R.W.B., R.T.K.), Tampa, Florida, USA

      2000

      Jaeb Center for Health Research, 3010 East 138th Avenue, Suite 9, FL 33613, Tampa, USA

      JAEB Center for Health Research, Tampa, Florida

      1999

      Jaeb Center for Health Research, Tampa, Florida (R.W.B., R.L.G.); the University of California, Davis, Sacramento, California (M.J.M.); the University of Minnesota, Minneapolis, Minnesota (E.J.H.); the University of Texas Southwestern Medical Center, Dallas, Texas (H.D.C., E.L.H.); the Eye and Ear Institute, University of Pittsburgh, Pittsburgh, Pennsylvania (G.N.F.); the Virginia Mason Medical Center, Seattle, Washington (T.L.); the West Virginia University Health Sciences Center, Morgantown, West Virginia (M.S.M.); the Doheny Eye Institute, Los Angeles, California (R.E.S.); the Johns Hopkins Hospital, Baltimore, Maryland (W.J.S.); the Emory University School of Medicine, Atlanta, Georgia (R.D.S.); and the University of Illinois, Chicago, Illinois, U.S.A. (J.S.).

      Visual Field Reading Center, Department of Ophthalmology, University of California, Davis, Davis, California, USA

      1998

      Tampa, FL

      1997

      Jaeb Center for Health Research, 3010 East 138th Avenue, Tampa, FL 33613, USA

      1996

      Jaeb Center for Health Research, Inc., 3010 E. 138 Ave., Suite 9, Tampa, FL 33613

      1995

      Jaeb Center for Health Research, Tampa.

      for the Optic Neuritis Study Group

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Roy W Beck is among the top experts in the world.
      Concept World rank
      adolescents 4 #1
      410yearolds #1
      mreva #1
      ecd 500 cells #1
      overnight insulin suspension #1
      cds donor age #1
      development subgroups #1
      baseline greatest benefit #1
      pilot study cgm #1
      direcnet #1
      goldmann perimeter additional #1
      4sitting 1sitting #1
      programmed handheld device #1
      pump discontinuation factors #1
      continuousmonitoring control #1
      t1d 1 diabetes #1
      basal insulin exercise #1
      development combined outcome #1
      cgm satisfaction life #1
      75 corneas #1
      insulet medtronic #1
      manual refraction differences #1
      qol measures diabetes #1
      ophthalmology patient education #1
      combined outcome development #1
      communitydeveloped resources #1
      bgm tir #1
      ranibizumab factors #1
      conservative measures btx #1
      176 participants #1
      children bilateral nldo #1
      randomized trials corticosteroids #1
      data mmtt assessments #1
      deciliter glucose level #1
      cgm measurements outcomes #1
      814d #1
      cheiroarthropathy common disorder #1
      events tabs #1
      baseline bgm #1
      neuritis study #1
      240±100 #1
      parental satisfaction cgm #1
      addition intravitreous dexamethasone #1
      oct center #1
      monoclonal humanized bias #1
      ontt female humans #1
      england diabetic ketoacidosis #1
      life epiphora #1
      hypoglycemia current approaches #1
      ecd determination readers #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Roy W Beck

      KOL-Index: 23723

      OBJECTIVE: Evaluate intravitreal 0.5 mg ranibizumab or 4 mg triamcinolone combined with focal/grid laser compared with focal/grid laser alone for treatment of diabetic macular edema (DME).

      DESIGN: Multicenter, randomized clinical trial.

      PARTICIPANTS: A total of 854 study eyes of 691 participants with visual acuity (approximate Snellen equivalent) of 20/32 to 20/320 and DME involving the fovea.

      METHODS: Eyes were randomized to sham injection + prompt laser (n=293), 0.5 mg ranibizumab + ...

      Known for Prompt Laser | Monoclonal Antibodies | Diabetic Macular Edema | Visual Acuity Dme | 1 Year
      KOL-Index: 21860

      PURPOSE: To provide 2-year results comparing anti-vascular endothelial growth factor (VEGF) agents for center-involved diabetic macular edema (DME) using a standardized follow-up and retreatment regimen.

      DESIGN: Randomized clinical trial.

      PARTICIPANTS: Six hundred sixty participants with visual acuity (VA) impairment from DME.

      METHODS: Randomization to 2.0-mg aflibercept, 1.25-mg repackaged (compounded) bevacizumab, or 0.3-mg ranibizumab intravitreous injections performed up to monthly ...

      Known for Ranibizumab Bevacizumab | Randomized Clinical Trial | Baseline 2 Years | Injections Year | Diabetic Macular
      KOL-Index: 20521

      IMPORTANCE: Panretinal photocoagulation (PRP) is the standard treatment for reducing severe visual loss from proliferative diabetic retinopathy. However, PRP can damage the retina, resulting in peripheral vision loss or worsening diabetic macular edema (DME).

      OBJECTIVE: To evaluate the noninferiority of intravitreous ranibizumab compared with PRP for visual acuity outcomes in patients with proliferative diabetic retinopathy.

      DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial ...

      Known for Intravitreous Ranibizumab | 2 Years | Randomized Clinical Trial | Panretinal Photocoagulation | Diabetic Retinopathy
      KOL-Index: 19521

      OBJECTIVE: To evaluate the effectiveness of treatment of amblyopia in children aged 7 to 17 years.

      METHODS: At 49 clinical sites, 507 patients with amblyopic eye visual acuity ranging from 20/40 to 20/400 were provided with optimal optical correction and then randomized to a treatment group (2-6 hours per day of prescribed patching combined with near visual activities for all patients plus atropine sulfate for children aged 7 to 12 years) or an optical correction group (optical ...

      Known for Treatment Amblyopia | 7 Years | Optical Correction | Children Aged | Patients Atropine
      KOL-Index: 18902

      Importance: Adolescents and young adults with type 1 diabetes exhibit the worst glycemic control among individuals with type 1 diabetes across the lifespan. Although continuous glucose monitoring (CGM) has been shown to improve glycemic control in adults, its benefit in adolescents and young adults has not been demonstrated.

      Objective: To determine the effect of CGM on glycemic control in adolescents and young adults with type 1 diabetes.

      Design, Setting, and Participants: Randomized ...

      Known for Glycemic Control | Glucose Monitoring | Type 1 Diabetes | Adolescents Young Adults | 26 Weeks
      KOL-Index: 18692

      BACKGROUND: The relative efficacy and safety of intravitreous aflibercept, bevacizumab, and ranibizumab in the treatment of diabetic macular edema are unknown.

      METHODS: At 89 clinical sites, we randomly assigned 660 adults (mean age, 61±10 years) with diabetic macular edema involving the macular center to receive intravitreous aflibercept at a dose of 2.0 mg (224 participants), bevacizumab at a dose of 1.25 mg (218 participants), or ranibizumab at a dose of 0.3 mg (218 participants). The ...

      Known for Ranibizumab Bevacizumab | Diabetic Macular Edema | Visual Acuity | Baseline P0001 | Intravitreous Aflibercept
      KOL-Index: 18451

      Importance: Demonstrating that endothelial cell loss following Descemet stripping automated endothelial keratoplasty (DSAEK) is independent of donor cornea preservation time (PT) could increase the pool of corneal tissue available for keratoplasty.

      Objective: To determine whether endothelial cell loss 3 years after successful DSAEK is related to PT.

      Design, Setting, and Participants: A multicenter, double-masked, randomized clinical trial included 40 clinical sites (70 surgeons) in the ...

      Known for 3 Years | Endothelial Cell | Preservation Time | Descemet Stripping | Randomized Clinical Trial
      KOL-Index: 17861

      Importance: Ranibizumab is a viable treatment option for eyes with proliferative diabetic retinopathy (PDR) through 2 years. However, longer-term results are needed.

      Objective: To evaluate efficacy and safety of 0.5-mg intravitreous ranibizumab vs panretinal photocoagulation (PRP) over 5 years for PDR.

      Design, Setting, and Participants: Diabetic Retinopathy Clinical Research Network multicenter randomized clinical trial evaluated 394 study eyes with PDR enrolled February through December ...

      Known for Panretinal Photocoagulation | Intravitreous Ranibizumab | Clinical Trial | 5 Years | Visual Acuity
      KOL-Index: 17821

      IMPORTANCE: Comparisons of the relative effect of 3 anti-vascular endothelial growth factor agents to treat diabetic macular edema warrant further assessment.

      OBJECTIVE: To provide additional outcomes from a randomized trial evaluating 3 anti-vascular endothelial growth factor agents for diabetic macular edema within subgroups based on baseline visual acuity (VA) and central subfield thickness (CST) as evaluated on optical coherence tomography.

      DESIGN, SETTING, AND PARTICIPANTS: Post hoc ...

      Known for Diabetic Macular | Bevacizumab Ranibizumab | Visual Acuity | Retinal Thickness | Baseline Cst
      KOL-Index: 17476

      Importance: A binocular approach to treating anisometropic and strabismic amblyopia has recently been advocated. Initial studies have yielded promising results, suggesting that a larger randomized clinical trial is warranted.

      Objective: To compare visual acuity (VA) improvement in children with amblyopia treated with a binocular iPad game vs part-time patching.

      Design, Setting, and Participants: A multicenter, noninferiority randomized clinical trial was conducted in community and ...

      Known for Binocular Ipad Game | 16 Weeks | Children Aged | Randomized Clinical Trial | Preschool Computers
      KOL-Index: 17419

      BACKGROUND: The benefit of initiation of insulin pump therapy (continuous subcutaneous insulin infusion; CSII) in patients with type 1 diabetes using continuous glucose monitoring (CGM) has not been studied. We aimed to assess glycaemic outcomes when switching from multiple daily injections (MDI) to CSII in adults with type 1 diabetes using CGM.

      METHODS: In this multicentre, randomised controlled trial, 75 adults with type 1 diabetes in the CGM group of the DIAMOND trial were randomly ...

      Known for Type 1 Diabetes | Cgm Csii | Continuous Glucose Monitoring | Insulin Pump | Randomised Controlled Trial
      KOL-Index: 17211

      OBJECTIVE: To determine whether endothelial cell loss 5 years after successful corneal transplantation is related to the age of the donor.

      DESIGN: Multicenter, prospective, double-masked clinical trial.

      PARTICIPANTS: Three hundred forty-seven subjects participating in the Cornea Donor Study who had not experienced graft failure 5 years after corneal transplantation for a moderate-risk condition (principally Fuchs' dystrophy or pseudophakic corneal edema).

      TESTING: Specular microscopic ...

      Known for 5 Years | Cell Loss | Donor Age | Corneal Endothelial | Baseline Ecd
      KOL-Index: 17102

      OBJECTIVE: To report expanded 2-year follow-up of a previously reported randomized trial evaluating intravitreal 0.5 mg ranibizumab or 4 mg triamcinolone combined with focal/grid laser compared with focal/grid laser alone for treatment of diabetic macular edema (DME).

      DESIGN: Multicenter, randomized clinical trial.

      PARTICIPANTS: A total of 854 study eyes of 691 participants with visual acuity of 20/32 to 20/320 (approximate Snellen equivalent) and DME involving the fovea.

      METHODS: ...

      Known for Prompt Laser | Diabetic Macular Edema | Monoclonal Antibodies | Ranibizumab Dme | Year Follow
      KOL-Index: 17086

      PURPOSE: To evaluate optical coherence tomography (OCT) reproducibility in patients with diabetic macular edema (DME).

      DESIGN: Prospective 1-day observational study.

      PARTICIPANTS: Two hundred twelve eyes of 107 patients with DME involving the macular center by clinical examination and OCT central subfield thickness of > or =225 microm.

      METHODS: Retinal thickness was measured with the OCT3 system, and scans were evaluated by a reading center. Reproducibility of retinal thickness ...

      Known for Macular Thickness | Optical Coherence | Patients Dme | Central Subfield | Center Point
      KOL-Index: 16753

      IMPORTANCE: Previous studies assessing the effect of metformin on glycemic control in adolescents with type 1 diabetes have produced inconclusive results.

      OBJECTIVE: To assess the efficacy and safety of metformin as an adjunct to insulin in treating overweight adolescents with type 1 diabetes.

      DESIGN, SETTING, AND PARTICIPANTS: Multicenter (26 pediatric endocrinology clinics), double-blind, placebo-controlled randomized clinical trial involving 140 adolescents aged 12.1 to 19.6 years ...

      Known for Glycemic Control | Type 1 Diabetes | Participants Metformin | Placebo Difference | Baseline Hba1c

      Key People For Type 1 Diabetes

      Top KOLs in the world
      #1
      John M Lachin
      type 1 diabetes cardiovascular disease complications trial
      #2
      David Matthew Nathan
      type 2 diabetes insulin resistance cardiovascular disease
      #3
      William V Tamborlane
      type 1 diabetes young children growth hormone
      #4
      Patricia A Cleary
      type 1 diabetes optic neuritis intensive therapy
      #5
      George S Eisenbarth
      type 1 diabetes nod mice celiac disease
      #6
      Marian J Rewers
      type 1 diabetes islet autoimmunity celiac disease

      Jaeb Center for Health Research, Tampa, Florida 33647, USA | Jaeb Center for Health Research Foundation, Inc., Tampa, Florida, USA. | Jaeb Center for Health Research, Tampa, FL. | Jaeb Center for Health Research Foundation, Inc. | Jaeb Center for Hea

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.